Publication | Closed Access
The EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’) is an effective inhibitor of tamoxifen-resistant breast cancer growth
20
Citations
0
References
2001
Year
Breast OncologyOncologyMedicineCancer Cell BiologyEffective Inhibitor‘ Iressa ’Breast CancerAnti-cancer AgentCancer TreatmentPharmacologyCell BiologyTumor BiologyCancer Growth
No additional data available for this publication yet. Check back later!